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Abstract
With transcatheter aortic valve implantation (TAVI) technology 
expanding its indications for low-risk patients, the number of TAVI-
eligible patients will globally grow, requiring a better understanding 
about the second-best access choice. Regarding the potential 
access sites, the transfemoral retrograde route is recognized as the 
standard approach and first choice according to current guidelines. 
However, this approach is not suitable in up to 10-15% of patients, 
for whom an alternative non-femoral access is required. Among 
the alternative non-femoral routes, the transaxillary approach has 
received increasing recognition due to its proximity and relatively 
straight course from the axillary artery to the aortic annulus, which 
provides a more accurate device deployment. Here we discuss some 
particular aspects of the transaxillary access, either percutaneously 
performed or by cutdown dissection.
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) is a well-
established treatment option for patients with severe 
symptomatic aortic stenosis (AS) regardless of the risk class, but 
especially in those who are inoperable or at high surgical risk.
Among the potential access sites, the transfemoral (TF) 
retrograde route is recognized as the standard approach and 
first choice according to current guidelines[1,2]. At the beginning 
of TAVI experience, however, alternative non-TF accesses were 
needed in up to 30% of patients[3], and even now, they are still 
indicated in 10-15% of the procedures[4,5].
Hostile aorto-iliofemoral anatomy due to extensive 
calcification, atherosclerosis, tortuosity, small vessel diameter, 
or presence of previously implanted arterial grafts represent the 
main reasons for TF access preclusion[4] (Figure 1). In this setting, 
transapical, direct aortic, transcarotid, transcaval, and trans-
subclavian/transaxillary (TAx) are possible alternative routes. 
Among these options, the TAx approach has received increasing 
recognition and has currently been used in up to 20% of TAVI 
procedures in some centers[6,7].
One of the TAx advantages is the proximity and relatively 
straight course from the axillary artery to the aortic annulus, 
which provides a more accurate device deployment[8]. Despite 
this theoretical benefit, the lack of randomized clinical trials and 
evidence-based guideline recommendations make the TAx role, 
as the second route of choice, to be questionable.
Here we discuss some particular aspects of the TAx access, 
either percutaneously performed or by cutdown dissection.
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Axillary Artery Anatomy
Since in the majority of TAVI performed via trans-subclavian 
or TAx, the point of artery access is at the lateral border of the first 
rib[9], in this paper, we will unify the terminology, referring to all 
cases as TAx route.
The axillary artery starts at the lateral border of the first rib 
and can be divided into three segments. The first segment is 
between the lateral border of the first rib and the medial border 
of the pectoralis minor; the second segment is behind the 
pectoralis minor; and the third segment is between the lateral 
border of the pectoralis minor and the inferior border of the teres 
major muscle[9].
Previous studies have demonstrated that the mean vessel 
diameter is about 6.38 mm in the right axillary artery and 6.52 mm 
in the left one[10], which means that it can accommodate sheaths 
with an outer diameter of up to 18 Fr. Moreover, this vessel is 
rarely affected by significant atherosclerosis (2.1% atherosclerotic 
disease in the axillary artery vs. 19.8% in the common femoral 
artery)[10].
Comparing tissue elasticity, it is remarkable that the axillary 
artery has more elastic walls, while the femoral artery is more 
rigid due to muscular and fibrous components. This histological 
characteristic may have an impact on the efficacy of vascular 
closure devices used in axillary position[9].
Procedure Details
Preoperative high-resolution computed tomography scan 
aiming to screen the axillary artery suitability and plan the 
procedure is an essential step for a well-succeeded intervention. 
The critical points that should be evaluated are the vessel 
diameter, the degree of tortuosity, the relationship with side 
branches, and the presence and extension of calcifications 
(Figure 2).
According to Schäfer et al.[9], three anatomical criteria must 
be taken into account when considering TAx approach[11]:
1. Subclavian or axillary artery diameter ≥ 6 mm;
2. Absence of heavy calcification, excessive kinking, or severe 
stenosis of the vessel to be accessed, unsuitable for balloon 
angioplasty;
3. In patients with a patent left internal mammary artery 
(LIMA) coronary bypass graft, a minimal vessel diameter 
of 7-8 mm and no significant atherosclerotic disease 
proximal to or at the ostium of the LIMA, in order to prevent 
myocardial ischemia.
The authors also emphasized that ipsilateral implanted 
pacemakers are not a contraindication for TAx approach.
Similar to these recommendations, in the recent Evolut 
Low-Risk trial, anatomical exclusion criteria were vessel mean 
diameter < 5.0 mm for Evolut R 23, 26, or 29; and < 5.5 mm for 
Evolut R 34 or Evolut PRO. If a patent LIMA graft was present, 
these values were modified to < 5.5 mm for Evolut R 23, 26, or 
29; and < 6.0 mm for Corevalve 31, Evolut R 34, or Evolut PRO[12].
In terms of technical aspects, the axillary artery can be 
reached by surgical cutdown or by totally percutaneous 
puncture. Regarding the site choice (right or left), it requires 
consideration of several factors. In general, the left axillary artery 
is preferred as it allows better coaxial orientation, decreases the 
chance of carotid compromise, and can be advantageous in 
right-handed patients. Other factors to be considered are the 
aortic annular angle and the takeoff angulation of the subclavian 
and innominate artery with the aortic arch. An angle > 30° 
between the annular plane and the right subclavian horizontal 
axis or > 70° between the annular plane and the left subclavian 
(i.e., “horizontal aorta”) typically means a contraindication due 
to difficulties in achieving coaxiality. Type 1 arch (all three great 
vessels originating from the transverse arch) also represents a 
Fig. 1 –  Computed tomography angiography reconstruction showing extensive aorta calcification (A) and important peripheral artery disease 
with circumferential calcification precluding transfemoral access (B).
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reason to avoid a right-sided approach, especially if the 
innominate artery arises distal on the arch. On the other 
hand, left-sided access may be challenging if the left 
subclavian artery is retroflexed towards the descending 
aorta, or with a steep subclavian to arch angulation (> 
80°)[13,14].
Despite the previous belief that the TAx approach 
requires general anesthesia, currently, about 46% of 
TAx-TAVI are done with local anesthesia and conscious 
sedation, especially during totally percutaneous access[15]. 
This approach might reduce procedural time, respiratory 
complications, postoperative delirium, and length of 
hospital stay[11].
Surgical Axillary Artery Approach
In this approach, the TAVI is directly delivered via 
subclavian/axillary artery. To perform the cutdown 
technique, the access is obtained by tissue dissection 
followed by placement of a double purse-string suture 
and direct cannulation; or by an arteriotomy, with 
attachment of a Dacron® graft[16].
A direct cannulation approach begins with axillary 
artery exposition through a small, 3-5-cm transversal, infra-
clavicular incision, performed 1 cm below and parallel 
to the clavicle. The pectoralis major muscle is slipped, 
the artery is exposed and encircled with soft rubber 
vessel loops (Figure 3). Attention is required to avoid 
damaging the brachial plexus. A double horizontal 5-0 
polypropylene purse-string is performed, and the artery 
is punctured in the center of the purse-string. Following 
heparin administration (aiming to achieve an activated 
clotting time > 250 seconds), a 10 Fr sheath is placed 
over a soft, J-tip, 0.035 wire. The guidewire is switched 
A B
C D
Fig. 2 - Transaxillary access evaluation. Axillary artery reconstruction 
in computed tomography (A-B). Vessel diameter, degree of tortuosity, 
relationship with side branches, and presence and extension of calcifications 
evaluation (B). Mean diameter suitable to transaxillary access (≥ 6 mm).
Fig. 3 - Axillary artery exposed and isolated with the use of two rubber 
vascular loops passed around its proximal and distal portions.
for a stiff wire positioned in the apex of the left ventricle, 
using standard catheter-exchange techniques to cross 
the aortic valve. The 10 Fr introducer is exchanged by the 
delivery system. From this point, the procedure follows 
the same technique used for the TF route. At the end of 
the procedure, hemostasis is achieved by tightening the 
purse-string sutures, and the skin layers are closed in the 
usual fashion.
In the Dacron graft approach[16], a similar skin incision 
is carried out, the vessel is isolated with the use of two 
rubber vascular loops passed around its proximal and 
distal portions. A small incision in the anterior axillary 
wall is performed and a Dacron tube graft (usually 8 mm 
diameter x 15 cm length) is anastomosed using a 5-0 
polypropylene (termino-lateral anastomosis). The Dacron 
graft is then clamped, and the proximal axillary artery is 
briefly unclamped to verify/optimize hemostasis. The 
tube is exteriorized through a second smaller and more 
lateral incision. The sheath is then introduced through 
the Dacron tube graft (Figure 4). At the end, the sheath 
is removed, and the graft is clamped with vascular 
surgical staple clips just above the anastomosis with 
the subclavian/axillary artery, avoiding any additional 
manipulation of the vessel. One of the Dacron graft 
approach main advantages is the cardiac surgeons' 
familiarity with this method since the axillary artery is 
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frequently cannulated during aorta surgeries or ventricular assist 
device implantation. Besides, the incision is well tolerated by 
patients, associated with satisfying cosmetic results, and early 
mobilization[17]. On the other hand, a significant learning curve 
has been described, with technical proficiency beginning to 
develop at the 25th case, and completing only after 50 cases[18].
Percutaneous Axillary Artery Approach
The potential benefits of percutaneous TAx access over other 
non-TF options are the maintenance of left ventricular integrity 
(in contrast to transapical) and the absence of chest opening 
(in comparison to direct aortic access), reducing procedural 
complexity and invasiveness[4]. Through this method, it is possible 
to offer a minimalist TAVI approach also to those patients with 
suboptimal femoral arteries[11]. A possible TAx limitation, however, 
is the assumed risk of vascular complications and bleeding[4].
The ideal site for percutaneous axillary access is its first 
segment, just proximal to the thoracoacromial branch. This site 
is chosen based on invariant position and absence of overlying 
nerves or veins[19]. Besides this, some authors argue that, in this 
position, the axillary artery could be easily manually compressed 
against the second rib[13].
A totally percutaneous axillary approach was described for 
the first time in 2012 by Schäfer et al.[9] in a cohort of 24 high-risk 
patients (mean logistic European System for Cardiac Operative 
Risk Evaluation I [EuroScore I] score 35.3±22.8%; Society of 
Thoracic Surgeons [STS] score > 10%). The authors reported 
no major adverse cardiac or cerebrovascular events, and no 
Fig. 4 - Transaxillary transcatheter aortic valve implantation performed through a Dacron tube graft insertion. Dacron tube graft anastomosed 
with the axillary artery (A). Sheath introduced through the Dacron tube graft (B).
Fig. 5 - Fluoroscopic and angiography-guided axillary artery approach. Contrast injection aiming to mark the axillary artery trajectory (A). Axillary 
artery puncture using as reference fluoroscopic landmarks and a guidewire inserted through the radial artery (B). Perclose technique using the 
Perclose/ProGlide Suture-Mediated Closure System (C). Transcatheter aortic valve implantation deployment (D). Final angiographic control (E). 
Final skin incision aspect (F).
A B
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major vascular complications. Device success was obtained 
in 95.8%, and the 30-day mortality was 8.3%. A particularly 
interesting observation was that, when the ProStar system was 
used as vascular closure device, 29.2% of patients (n=7) needed 
a vascular stent placement because of persistent bleeding or 
closure failure, whereas when the Perclose ProGlide system was 
used, no complications were observed.
The expanded experience of the so-called “Hamburg Sankt 
Georg Approach”, comprising 100 consecutive cases, was 
published in 2017, using the left artery in 85% and the right 
artery in 15% of cases. Device success was achieved in 95%, there 
was one procedural death (annular rupture), one peri-procedural 
transient ischemic attack, and the one-year mortality was 14.8%. 
Vascular stent placement was required in 11 patients, mainly in 
the early phase (seven reported in the initial study phase and four 
in the extended follow-up). These data made authors conclude 
that a learning curve clearly exists, and the complication rate 
tends to decrease with growing experience[4].
Regarding procedural details, all axillary punctures were 
performed guided by fluoroscopy, using a regular J-wire as a 
landmark (an example of this approach is showed in Figure 5). 
The mean minimum vessel diameter was 6.85±0.17 mm, and 
nine patients presented moderate access vessel calcification. 
The puncture was performed in the proximal location of the 
first segment, at a distance of 1.2±0.9 cm to the lateral border 
of the rib, to avoid pneumothorax and to have the possibility of 
manual artery compression[4,9]. Nowadays, ultrasound-guided 
axillary artery puncture has been used as an alternative access to 
fluoroscopy or angiography-guided punctures (Figure 6).
DISCUSSION
Since the first TAx-TAVI case performed by Ruge H. in 2008[20], 
several technical improvements and increased operator familiarity 
with the method contributed to make this approach the second 
route of choice in many TAVI centers. In this pioneer report, a patient 
with aortoiliac occlusive disease and concomitant left subclavian 
arterial stenosis received a TAVI through the right axillary artery. 
One year later, the left axillary artery access was described[21] in a 
woman with severe AS and small iliofemoral arteries. Following 
these pioneer reports, many series of cases started to describe the 
outcomes associated with the TAx route.
One of the first analysis from the Italian national registry 
showed that, even when performed in higher-risk patients, TAx-
TAVI presented similar outcomes compared to the TF route in terms 
of procedural success (100% vs. 98.4%; P=0.62), intraprocedural 
mortality (0% vs. 0.9%; P=1.00), and valve-related adverse events 
(13.6% vs. 13.9%; P=0.79)[22]. When propensity score matching 
was used, the TAx approach showed an equivalent two-year 
survival (74.0±4.0% in TAx vs. 73.7±3.9% in TF; P=0.78), and lower 
rates of acute kidney injury (4.3% vs. 9.9%; P=0.02), minor vascular 
complications (2.1% vs. 11.3%; P=0.003), and major bleeding due 
to vascular complication (0.7% vs. 4.3%; P=0.05)[23].
Amat-Santos also suggested that, despite a higher logistic 
EuroScore (23.7±1.92 vs. 21.17±3.51; P=0.04) and more prevalent 
coronary and peripheral artery disease, TAx access was performed 
with a similar 30-day stroke rate, need for new pacemaker 
Fig. 6 - Ultrasound-guided axillary artery puncture. Ultrasound short 
(A) and long-axis (B) axillary artery evaluation. Out-of-plane (shot-
axis) (C) and in-plane (longitudinal-axis) axillary artery puncture (D). 
Guidewire (E) and short sheath insertion (F).
implantation, major vascular complications, and acute kidney 
injury requiring dialysis when compared to the TF approach[24].
In addition to the aforementioned data, no differences 
between TF and TAx approaches in terms of procedural success 
rate (97.9% TAx vs. 95-100% TF), neurological events (2.1% TAx vs. 
1.4-6.7% TF), new pacemaker implant (24.7% TAx vs. 3.4-34.1% 
TF)[25], procedural time, procedural success[8], paravalvular leak, 
conversion to open-heart surgery, and hospital length of stay[26] 
were also suggested.
Comparing the most common used routes, a meta-analysis 
published in 2015 encompassing 17,020 patients (11,079 TF and 
5,941 non-TF [5,119 transapical, 514 TAx, 305 transaortic, and 
three transcarotid)] showed a lower 30-day (4.7% TF vs. 8.1% 
non-TF; P<0.01) and one-year mortality rate (16.4% TF vs. 24.8% 
non-TF; P<0.01) in patients who underwent a TAVI procedure 
through TF access. TF access was, however, associated with 
higher incidence of vascular complications (odds ratio [OR] 2.1; 
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bleeding (OR 1.01; 95% CI 0.81-1.27) and cerebrovascular events 
(1.6% vs. 2.1%; P=0.31) compared to TAx access[27].
Trend analysis revealed that, among 3,628 patients from the STS/
American College of Cardiology Transcatheter Valve Therapy registry 
who received a balloon-expandable SAPIEN 3 prosthesis (Edwards 
Lifesciences LLC, Irvine, California, United States of America) via non-
TF access, the axillary artery was used in 20.2% in the third quarter 
of 2015, and in 49.0% in the fourth quarter of 2017 (P<0.001). This 
growth was accompanied by a concomitant decrease in transapical 
and transaortic use (from 61.9% in the third quarter of 2015 to 35.3% 
in the fourth quarter of 2017; P<0.001). Comparing both methods 
by propensity score matching, the TAx route was associated with 
lower 30-day mortality (5.3% vs. 8.4%; P<0.01), new-onset atrial 
fibrillation (2% vs. 13%; P<0.001), new dialysis requirement (0.7% 
vs. 2.5%; P=0.001), rehospitalization (11.6% vs. 15.1%; P=0.03), and 
shorter intensive care unit (26.3 hours vs. 47 hours; P<0.001), and 
hospital length of stay (three days vs. six days; P<0.001), but a higher 
stroke rate (6.3% vs. 3.1%; P<0.05)[28].
A sub-analysis from this same study showed no significant 
difference in adverse procedural outcomes when percutaneous 
axillary artery access was compared to the surgical one. Despite 
slightly shorter fluoroscopy times and longer intensive care unit 
length of stay in the surgical group, there were no differences in 
30-day mortality, stroke, new-onset atrial fibrillation, readmission, 
new requirement for dialysis, new pacemaker implantation, life-
threatening bleeding, and major vascular complication [28].
This same tendency favoring the TAx approach as the second 
route across the years was seen with the self-expanding Evolut 
R system (Medtronic, Minneapolis, Minnesota, United States of 
America), with a ratio of 3.3:1 between TAx and direct aortic route[29].
CONCLUSION
With transcatheter valve technology expanding its 
indications for low-risk patients, the number of TAVI-eligible 
patients will globally grow, requiring a better understanding 
about the second-best access choice.
Although no direct comparison from prospective, 
randomized trials is available, the TAx approach has emerged as 
a feasible alternative, with similar results to the TF approach, and 
better than other non-TF approaches. Vascular access route and 
technical aspects should be a patient-centered decision rather 
than an operator-driven preference.
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